vaccine temperature News
-
Vaccine Temperature Monitoring Made Effortless with the VFC2000
MadgeTech is eliminating the complexity of vaccine temperature monitoring routines with the new VFC2000 Vaccine Temperature Monitoring System. For less than $200, the VFC2000 is the ultimate data logging solution for validating VFC and CDC compliance. The VFC2000 features a digital display showing minimum, maximum, and current temperature readings. Designed with at Type K thermocouple and glycol ...
-
Continuous Vaccine Temperature Monitoring Puts MadgeTech on the Frontlines
MadgeTech is excited to announce the launch of two temperature monitoring systems designed specifically to meet the strict storage requirements surrounding the new COVID-19 vaccines. Capable of measuring and recording temperatures as low as -100 °C, the MadgeTech VFC2000 and VTMS data logging systems come with all the tools needed to ensure vaccine distribution and storage plans are operating ...
-
Medical Refrigerators for Storing Covid-19 Vaccine
And it happened – on December 21, the European Commission approved the conditional approval of the COVID-19 vaccine developed by Pfizer and BioNTech. The decision was based on the opinion of the Committee for Medicinal Products for Human Use at the European Medicines Agency. We’ve been all waiting impatiently for this decision – it would probably not be an ...
-
AKCP Develops COVID-19 Vaccine Delivery Monitoring
AKCP Coronavirus Vaccine Delivery Monitoring Solution The COVID-19 vaccines coming from Pfizer and Moderna both require storage and transportation at low temperatures. The Pfizer vaccine at -70°C +/- 10°C whereas Moderna requires -20°C. Both can be transferred to standard medical refrigerators for short periods of time. The latest COVID-19 vaccine to be announced from AstraZeneca ...
By AKCP
-
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation’s (NASDAQ:ZSAN) proprietary ...
-
Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a company addressing major global infectious disease threats through the development of fully synthetic CD8+ T-Cell Adaptive Vaccines, today announces that it has entered into an agreement with ATCC to progress preclinical development of its Yellow Fever booster vaccine program. ATCC is a non-profit ...
-
Universal flu vaccine pioneer EnGen Bio announces a registered equity crowdfunding campaign, in partnership with WeFunder.
EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global Influenza Strategy (2019–2030) ...
-
BioLingus to Develop a Sublingual Vaccine for COVID in Cooperation With the Korean CHA Vaccine Institute and PanGen Biotech
Biolingus IP II GmbH and the CHA Vaccine Institute Co., Ltd., with support from the Korean biotech company PanGen Biotech Inc., will collaborate to develop a sublingual vaccine for COVID. The project has received research funding from The Research Investment for Global Health Technology Fund (The RIGHT Fund). The RIGHT Fund is a Public-Private Partnership (PPP) funding agency between the ...
By BioLingus AG
-
EnGen Bio announces a registered equity crowdfunding campaign, in partnership with WeFunder.
EnGen Bio is an early stage biotechnology company pioneering a new approach to preventing and treating influenza, with the goal of an effective, easy-to-manufacture, shelf-stable universal flu vaccine that should confer long-term immunity to all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health ...
-
Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that it has signed heads of terms for a collaboration with the Molecular Biology Institute of Paraná (IBMP) in Brazil. IBMP is a ...
-
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I human trials Emergex’s universal influenza vaccine is a radically different approach to inducing influenza immunity by employing the use of a combination of: Highly conserved Class I peptides from non-structural proteins (NSP) representative of pandemic influenza A strains which ...
-
Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives
Emergex’s CD8+ T cell Adaptive Vaccine platform will now be used to generate a tularemia vaccine candidate that provides a cytotoxic (killing of infected cells) CD8+ T cell response and offers a means for rapid development suitable for deployment as a medical countermeasure. Emergex’s ongoing Phase I clinical trials on vaccine candidates for Dengue Fever and COVID-19 are evaluating ...
-
Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
Both studies fully recruited, with data from the Dengue Fever study anticipated in the summer Preclinical data for Emergex’s Coronavirus vaccine candidate suggests that it could provide heterologous immunity to viruses from the same family Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major ...
-
Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic Priming T cell Adaptive Vaccines, today announces that it has been awarded a £490,525 grant by the UK government’s Department of Health and Social Care (‘DHSC’) to advance a synthetic T ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you